Quick Answer
Elicio Therapeutics, Inc. reported Earnings Per Share Diluted of $2.58 (loss) per share for the year ending 2025.
- Elicio Therapeutics, Inc. showed an increase of +39.3% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Elicio Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $0.91 (loss) per share | Q2 2020: $1.40 (loss) per share | Q3 2020: $1.19 (loss) per share | Q1 2021: $1.56 (loss) per share | Q2 2021: $0.58 (loss) per share | Q3 2021: $0.53 (loss) per share | Q1 2022: $0.48 (loss) per share | Q2 2022: $23.20 (loss) per share | Q3 2022: $22.67 (loss) per share | Q1 2023: $24.77 (loss) per share | Q2 2023: $2.61 (loss) per share | Q3 2023: $1.27 (loss) per share | Q1 2024: $1.15 (loss) per share | Q2 2024: $0.64 (loss) per share | Q3 2024: $1.39 (loss) per share | Q1 2025: $0.87 (loss) per share | Q2 2025: $0.66 (loss) per share | Q3 2025: $0.60 (loss) per share.
- Over the full 6 years of available data (2020 to 2025), Elicio Therapeutics, Inc.'s Earnings Per Share Diluted has grown by 52.5%.
- Historical annual values: Fiscal year 2025: $2.58 (loss) per share | Fiscal year 2024: $4.25 (loss) per share | Fiscal year 2023: $6.96 (loss) per share | Fiscal year 2022: $89.27 (loss) per share | Fiscal year 2021: $1.93 (loss) per share | Fiscal year 2020: $5.43 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: